Paul D. Thompson MDChief of Cardiology – Emeritus, Hartford Hospital, Hartford, Connecticut; Professor of Medicine, University of Connecticut, Storrs, Connecticut
Paul D. Thompson, MD, graduated from Tufts College and from Tufts Medical School. He served as a medical intern and resident at Tufts New England Medical Center and completed his training in cardiology at Stanford Medical Center.
Dr. Thompson is Chief of Cardiology – Emeritus, Hartford Hospital, Hartford, Connecticut, and Professor of Medicine at the University of Connecticut. He previously was Professor of Medicine at the University of Pittsburgh from 1992 to 1997 and on the faculty of Brown University from 1978 to 1992. He has authored over 450 scientific articles on topics which include: the treatment of cardiovascular risk factors, the effects of exercise training on preventing and treating heart disease; the risk of sudden death during exercise; the effects of statins on muscle function, and genetic factors affecting the exercise response. His past and present NIH funding includes the Preventive Cardiology Academic Award as well as studies examining the effect of exercise training on HDL metabolism; the effect of testosterone on endothelial function; genetic factors affecting muscle hypertrophy with exercise training; the effects of statins on skeletal muscle strength; the effects of Coenzyme Q10 on statin myalgia; and genetic factors increasing the risk of statin myalgia. Dr. Thompson is the Editor of the book Exercise and Sports Cardiology. He is a Past President of the American College of Sports Medicine.
Paul D. Thompson, MD, has been a member of the Speakers’ Bureau for Regeneron, Sanofi, Boehringer-Ingelheim, Amgen, and Amarin; has served as a consultant for Amgen, Regeneron, Esperion, and Sanofi; has received research support from Sanofi, Regeneron, Esperion, Amarin, and Pfizer; owns stock in Abbvie, Abbott Labs, CVS, General Electric, Johnson & Johnson, Medtronic, Myocardia, and Sarepta; and has provided legal consultation on exercise-related cardiac events and statin myopathy.
Recent Contributions to PracticeUpdate:
- The Physical Activity Paradox in Cardiovascular Disease and All-Cause Mortality
- Prevalence of Inflammatory Heart Disease Among Professional Athletes With Prior COVID-19 Infection Who Received Systematic Return-to-Play Cardiac Screening
- Non-HDL Cholesterol Measured Earlier in Life Associated With Coronary Artery Calcification in Mid-Adulthood
- Evaluation for Myocarditis in Competitive Student Athletes Recovering From COVID-19 With Cardiac MRI
- Association of Physical Activity Intensity With Mortality
- 2020 Top Stories in Cardiology: So, I Guess It Isn’t Always the LDL Receptor
- Cardiovascular Benefits of a Mediterranean Diet and Intermittent Fasting
- High-Intensity Interval Training in Cardiac Rehabilitation Is Feasible and Effective
- Sedentary Behavior and Cancer Mortality in Middle-Aged and Older US Adults
- Exercise ECG and Coronary CTA for Patients With Suspected Stable Angina Pectoris